Olix previously signed an exclusive technology transfer agreement with Eli Lilly for siRNA targeting MASH (Metabolic Dysfunction-Associated Steatohepatitis) and cardiovascular/metabolic diseases, leveraging its RNA interference (RNAi)-based drug platform technology. As of 2026, Phase 1 clinical trials for OLX702A are underway in Australia, with Phase 2 entry anticipated this year. As of March 2026, Olix's stock price surged by +15.78% in a short period, receiving market re-evaluation. The 'Olix 2.0 Roadmap' presented at JPM 2026 garnered further attention with the expansion of its CNS platform and the unveiling of a new obesity-targeting ALK7 program. LegChem Bio achieved a significant milestone by out-licensing LCB97 (L1CAM-targeted solid tumor ADC) for approximately 940 billion Korean Won, despite being in the preclinical stage, thanks to its proprietary ADC platform 'ConjuALL'. LCB84 (TROP2 ADC) is expected to generate an additional 270 billion Korean Won if Janssen exercises its option upon completion of Phase 1 and entry into Phase 2. The company also showed a positive sign for turning profitable, recording consolidated sales of 141.6 billion Korean Won (+12.4% YoY) in 2025. A commonality between the two companies is their ability to forge multi-trillion won deals with global big pharma, establishing a new formula for K-Bio through their proprietary platform technologies. With the high likelihood of additional data presentations at major conferences in the first half of 2026, such as AACR (April) and ASCO (May), both companies are considered leading K-Bio theme stocks to watch this year.